期刊
PATHOLOGY RESEARCH AND PRACTICE
卷 215, 期 12, 页码 -出版社
ELSEVIER GMBH
DOI: 10.1016/j.prp.2019.152691
关键词
Dendritic cells; Vaccine; Pancreatic cancer; Combination therapies
类别
资金
- National Cancer Institute [R01CA209886, R01CA196967]
- key research and development program of Tianjin Municipal Science and Technology Commission [17YFZCSY00870]
- 2019 Harold E. Eisenberg Foundation Scholar Award
- Fishel Fellowship Award at the Robert H. Lurie Comprehensive Cancer Center
Despite significant advances over the past decades of research, pancreatic cancer (PC) continues to have the worst 5-year survival of any malignancy. Dendritic cells (DCs) are the most potent professional antigen-presenting cells and are involved in the induction and regulation of antitumor immune responses. DC-based immunotherapy has been used in clinical trials for PC. Although safety, efficacy, and immune activation were reported in patients with PC, DC vaccines have not yet fulfilled their promise. Additional strategies for combinatorial approaches aimed to augment and sustain the antitumor specific immune response elicited by DC vaccines are currently being investigated. Here, we will discuss DC vaccination immunotherapies that are currently under preclinical and clinical investigation and potential combination approaches for treating and improving the survival of PC patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据